Pharmamar
Otro sitio realizado con WordPress
- Website
- pharmamar.com · all feeds from this site
- Feed URL
https://pharmamar.com/feed/
Read it in your FeedListing reader
Or add to: Feedly Inoreader Raw feed
Latest posts
-
PharmaMar Group presents financial results as of September 30th, 2026
PharmaMar Group reported a 12% increase in total revenue during the first nine months of the year, reaching €146.9 million. Recurring revenue, calculated as net sales plus royalties received from our partners, grew by 30% to €137.4 million.
-
PharmaMar leads the MARINTE project to discover new marine-based cancer therapies that target proteins involved in tumor growth
The MARINTE project (Marine Small-Molecule Modulators of αV Integrins), led by PharmaMar (MSE: PHM) in collaboration with leading Spanish research groups, was launched with the goal of discovering and validating […]
-
PharmaMar presents latest data on PM54 and will hold a Satellite Symposium on Small Cell Lung Cancer at ESMO 2026 in Madrid
PharmaMar, leader in the research, development, and commercialization of marine-derived oncology therapies will participate in the European Society Medical Oncology (ESMO), taking place in Madrid from October 23rd to 27th.
-
The United Kingdom approves Zepzelca® (lurbinectedin) by PharmaMar in combination with atezolizumab for first-line maintenance treatment of small cell lung cancer
PharmaMar (MSE: PHM) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval in the United Kingdom for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) as […]
-
PharmaMar Celebrates 40 Years of Marine-derived Oncology Innovation and Reinforces Its Commitment to R&D
PharmaMar (MSE: PHM) a biopharmaceutical company and a global leader in the research, development, and commercialization of marine-derived oncology therapies, is celebrating its 40th anniversary. Four decades of scientific innovation […]
-
PharmaMar receives FDA clearance for the PM54 platform trial STARFISH-54 to accelerate combination development across solid tumors
PharmaMar (MSE: PHM) has announced that the American Food and Drug Administration (FDA) has provided clearance for platform trial STARFISH-54 for PM54 to evaluate its activity in various solid tumors […]